Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Donald Trump’s new drug pricing order has the Indian pharmaceutical industry on edge. While CDMOs may benefit, generics and ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

On May 13, 2025, numerous companies, including Bharti Airtel and Tata Motors, will release their financial results.

The US government's order to pharma firms to lower the cost of prescription medicines within 30 days will not impact Indian ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

Cipla MD Umang Vohra assured that the US government's directive to lower prescription drug costs will not impact Indian ...

Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Drug major Cipla on Tuesday said its consolidated net profit increased 30 per cent to Rs 1,222 crore in the fourth quarter ...